Treatment Of Idiopathic Pulmonary Fibrosis
Publication Date: July 1, 2015
Key Points
Key Points
- Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause occurring in adults.
- Radiologic and/or histopathologic patterns are consistent with usual interstitial pneumonia.
- Significant advances have been recently made in the clinical management of IPF.
- All of the recommendations in favor of treatment are conditional, meaning that decisions to treat patients with IPF should be individualized. Clinicians should be cautious to not interpret recommendations with the same grade as having the same net effects.
- The recommendations in favor of treatment put a higher value on the potential benefit of patient-important outcomes such as disease progression as measured by FVC decline and mortality and a lower value on potentially significant adverse effects and the cost of treatment.
Treatment
...reatment...
...Recommended DrugsaHaving trouble viewing tab...
...le 2. Recommendations...
...atients with IPF, the guideline committe...
...nicians NOT use imatinib. ( Moderate...
...s NOT use warfarin anticoagulation in patients...
...icians NOT use the combination therapy of...
...NOT use ambrisentan, a selective E...
...nts with IPF, the guideline committee sug...
...se nintedanib. ( Moderate , C, M)695...
...irfenidone. ( Moderate , C, M)695
...icians NOT use sildenafil, a phosphodiesterase-5...
...ans NOT use bosentan or macitentan, both dual E...
...NOT use N-acetylcysteine monotherapy...
...regular anti-acid treatment. ( Ve...